Research Analysts Issue Forecasts for DYAI Q2 Earnings

Dyadic International Inc. (NASDAQ:DYAI) – Investment analysts at Zacks Research issued their Q2 2026 earnings per share estimates for Dyadic International in a report issued on Wednesday, May 20th. Zacks Research analyst J. Vandermosten anticipates that the biotechnology company will post earnings of ($0.03) per share for the quarter. The consensus estimate for Dyadic International’s current full-year earnings is ($0.12) per share. Zacks Research also issued estimates for Dyadic International’s Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.02) EPS and FY2028 earnings at ($0.01) EPS.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a research note on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $3.00.

Dyadic International Trading Up 2.3%

Shares of Dyadic International stock opened at $0.74 on Thursday. Dyadic International has a 12-month low of $0.65 and a 12-month high of $1.35. The stock has a market cap of $26.88 million, a P/E ratio of -3.21 and a beta of 1.18. The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 4.08. The business’s 50 day moving average is $0.81 and its 200-day moving average is $0.87.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The company had revenue of $1.11 million for the quarter, compared to analyst estimates of $0.90 million. Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%.

Hedge Funds Weigh In On Dyadic International

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE raised its stake in Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 26,965 shares during the period. Marathon Capital Management bought a new position in shares of Dyadic International during the 3rd quarter worth approximately $41,000. Geode Capital Management LLC boosted its stake in shares of Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after acquiring an additional 36,266 shares during the period. Truist Financial Corp increased its holdings in shares of Dyadic International by 30.5% during the 3rd quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock worth $385,000 after acquiring an additional 76,200 shares during the last quarter. Finally, Landscape Capital Management L.L.C. bought a new stake in Dyadic International in the 3rd quarter valued at $190,000. Institutional investors own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.